Lisinopril for renal protection
Pro Research Analysisby 
Searched over 200M research papers
Lisinopril for Renal Protection: A Comprehensive Review
Introduction to Lisinopril and Renal Protection
Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, is widely used for its renoprotective effects, particularly in patients with hypertension and diabetes. This article synthesizes research findings on the efficacy of lisinopril in protecting renal function across various conditions, including diabetic nephropathy, hypertensive nephropathy, and non-diabetic chronic renal diseases.
Antiproteinuric Effects of Lisinopril
Reduction of Proteinuria
Lisinopril has been shown to significantly reduce proteinuria, a key marker of renal damage. In a study involving rats with established adriamycin nephrosis, lisinopril reduced proteinuria by an average of 72%, which correlated with a reduction in glomerulosclerosis, a form of kidney scarring . This antiproteinuric effect is crucial as it predicts long-term renal protection.
Enhanced Effects with Sodium Depletion
The renoprotective effects of lisinopril are further enhanced by sodium depletion. In the same study, sodium depletion amplified the reduction in proteinuria and glomerulosclerosis, suggesting a synergistic effect between sodium intake and ACE inhibition .
Oxidative Stress and Renal Protection
Attenuation of Oxidative Injury
Lisinopril also mitigates oxidative stress, which is a significant contributor to renal damage. In hypertensive rats induced by l-NAME, lisinopril treatment reduced markers of oxidative stress, such as malondialdehyde (MDA), and increased antioxidant enzyme activities, including superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) . This reduction in oxidative stress markers indicates a protective effect on renal tissues.
Combination Therapies for Enhanced Renoprotection
Lisinopril and Avosentan
Combining lisinopril with other agents can enhance its renoprotective effects. For instance, the combination of lisinopril and the endothelin receptor antagonist avosentan in diabetic rats resulted in complete protection from tubulointerstitial damage and regression of glomerular lesions, which was not achieved by either drug alone . This suggests a synergistic effect that offers superior renal protection.
Lisinopril and l-Arginine
Similarly, combining lisinopril with l-arginine, a precursor of nitric oxide, in a rat model of membranous nephropathy showed significant reductions in proteinuria and improvements in renal function compared to lisinopril alone . This combination therapy also reduced endothelin-1 levels, further supporting its potential in severe nephropathies.
Lisinopril in Diabetic Nephropathy
Early Intervention in Diabetic Patients
In normotensive patients with insulin-dependent diabetes mellitus (IDDM) and early signs of nephropathy, lisinopril slowed the progression of renal disease. The greatest effect was observed in patients with microalbuminuria, where lisinopril significantly reduced urinary albumin excretion rates . This suggests that early intervention with lisinopril can be beneficial in preventing the progression of diabetic nephropathy.
Long-Term Effects in Hypertensive Diabetic Patients
In hypertensive non-insulin-dependent diabetes mellitus (NIDDM) patients with diabetic nephropathy, lisinopril was as effective as atenolol, a beta-blocker, in reducing the decline in kidney function over a 42-month period. However, lisinopril was more effective in reducing urinary albumin excretion, highlighting its specific renoprotective benefits .
Lisinopril in Non-Diabetic Nephropathies
Mild Proteinuric Non-Diabetic Nephropathies
Lisinopril has also shown efficacy in non-diabetic chronic renal diseases with mild proteinuria. In a study comparing lisinopril to other antihypertensive agents, lisinopril significantly slowed the decline in renal function, as measured by inulin clearance, over a 22.5-month period . This supports the use of lisinopril in a broader range of renal conditions beyond diabetes.
Conclusion
Lisinopril offers substantial renoprotective benefits across various renal conditions, primarily through its antiproteinuric and antioxidative effects. Its efficacy is enhanced when combined with other agents like avosentan or l-arginine. Early intervention, particularly in diabetic patients, can significantly slow the progression of renal disease. These findings underscore the importance of lisinopril in the management of renal protection.
Sources and full results
Most relevant research papers on this topic
Combining lisinopril and l-arginine slows disease progression and reduces endothelin-1 in passive Heymann nephritis.
Combining l-arginine with ACE inhibitors can slow disease progression and reduce endothelin-1 in patients with severe nephropathy not fully responsive to ACE inhibition.
Effect of Lisinopril on the progression of renal insufficiency in mild proteinuric non-diabetic nephropathies.
Lisinopril has a specific renoprotective effect in addition to blood pressure control in patients with mild proteinuria, slowing the progression of non-diabetic chronic renal diseases.
DOI